Research in Motion (RIMM) estimates cut at JP Morgan through 2014, JP Morgan said. Weaker outlook for Blackberry 7 sales.
Sarepta (SRPT) estimates, target boosted at JMP. Shares of SRPT now seen reaching $50, according to JMP Securities. Estimates also upped, given the clinical efficacy of its muscular dystrophy drug. Outperform rating.
>To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts